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Abstract
Introduction Breast cancer at a young age is associated with an
unfavorable prognosis. Very young patients with breast cancer
therefore are advised to undergo adjuvant chemotherapy
irrespective of tumor stage or grade. However, chemotherapy
alone may not be adequate in young patients with hormone
receptor-positive breast cancer. Therefore, we studied the
effect of adjuvant chemotherapy in young patients with breast
cancer in relation to hormone receptor status.
Methods Paraffin-embedded tumor material was collected from
480 early-stage breast cancer patients younger than 41 years
who participated in one of four European Organization for
Research and Treatment of Cancer trials. Using
immunohistochemistry on the whole series of tumors, we
assessed estrogen receptor (ER) status and progesterone
receptor (PgR) status in a standardized way. Endpoints in this
study were overall survival (OS) and distant metastasis-free
survival (DMFS). The median follow-up period was 7.3 years.
Results Overall, patients with ER-positive tumors had better OS
rates (hazard ratio [HR] 0.63; P = 0.02) compared with those
with ER-negative tumors. However, in the subgroup of patients
who received chemotherapy, no significant difference in OS
(HR 0.87; P = 0.63) and DMFS (HR 1.36; P = 0.23) was found
between patients with ER-positive tumors or those with ER-
negative tumors. These differences were similar for PgR status.
Conclusion Young patients with hormone receptor-positive
tumors benefit less from adjuvant systemic chemotherapy than
patients with hormone receptor-negative tumors. These results
confirm that chemotherapy alone cannot be considered optimal
adjuvant systemic treatment in breast cancer patients 40 years
old or younger with hormone receptor-positive tumors.
Introduction
Breast cancer in premenopausal women is associated with
worse outcome compared with postmenopausal patients [1].
Approximately 7% of women diagnosed with breast cancer
are younger than 40 years old [2]. Very young women (that is,
younger than 35 years old), especially, are at a high risk of
developing distant metastases. Therefore, they are recom-
mended to receive adjuvant systemic chemotherapy regard-
less of tumor stage or grade [3]. In addition, high local regional
recurrence rates after breast-conserving therapy have been
reported in young premenopausal patients with breast cancer
[4]. Although it is clear that young age is an independent prog-
nosticator of adverse outcome in breast cancer, controversies
regarding the optimal treatment in this population exist.
Adjuvant systemic chemotherapy in premenopausal patients
has been shown to improve survival [1], but controversy about
the role of chemotherapy in patients with hormone receptor-
positive tumors still exists. Aebi and colleagues [5] clearly
showed that the endocrine effects of chemotherapy alone
might not be sufficient for very young patients with breast can-
cer. In this study, it was shown that estrogen receptor (ER)-
CI = confidence interval; CMF = cyclophosphamide, methotrexate, and 5-fluorouracil; DMFS = distant metastasis-free survival; EORTC = European 
Organization for Research and Treatment of Cancer; ER = estrogen receptor; FAC = doxorubicin, 5-fluorouracil, and cyclophosphamide; FEC = 5-
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positive tumors in patients younger than 35 years and treated
with cyclophosphamide, methotrexate, and 5-fluorouracil
(CMF) had a significantly worse disease-free survival com-
pared with ER-negative patients.
To detect whether we could confirm these data by finding sim-
ilar results, we studied the efficacy of chemotherapy in young
patients with breast cancer according to ER status and pro-
gesterone receptor (PgR) status and selected patients 40
years old or younger at the time of primary diagnosis from four
European Organization for Research and Treatment of Cancer
(EORTC) trials that were conducted by the EORTC Breast
Cancer Group and Radiotherapy Group.
Materials and methods
Data were collected from four EORTC trials. In total, 9,938
patients participated in these trials; 934 of these patients were
40 years old or younger at the time of diagnosis. The trial
designs are summarized below:
EORTC trial 10801 (1980 to 1986, median follow-up 13.4
years) was conducted to assess the safety of breast-conserv-
ing treatment. In this trial, patients were randomly assigned
between breast-conserving surgery combined with radiother-
apy and radical mastectomy. Six cycles of adjuvant chemother-
apy with cyclophosphamide 100 mg/m2 given orally on days 1
to 14, methotrexate 40 mg/m2 given intravenously on days 1
and 8, and 5-fluorouracil 600 mg/m2 (CMF) given intrave-
nously on days 1 and 8 were indicated for all patients under
the age of 55 with positive nodes. A total of 902 patients were
randomly assigned [6].
EORTC trial 10854 (1986 to 1991, median follow-up 10.8
years) studied the question of whether one course of periop-
erative chemotherapy given directly after surgery yields better
results in terms of treatment outcome than surgery alone. Peri-
operative chemotherapy consisted of a single course of doxo-
rubicin 50 mg/m2, 5-fluorouracil 600 mg/m2, and
cyclophosphamide 600 mg/m2 (FAC) administered intrave-
nously within 36 hours after surgery. For axillary lymph node-
positive premenopausal patients in the perioperative chemo-
therapy group, adjuvant chemotherapy consisting of five
cycles of CMF was recommended. For node-positive patients
younger than 50 years who did not receive perioperative
chemotherapy, one conventional course of FAC followed by
five cycles of CMF after surgery was recommended. Postmen-
opausal patients were recommended to receive tamoxifen. A
total of 2,795 patients were included [7].
EORTC trial 10902 (1991 to 1999, median follow-up 6.1
years) was set up to determine the value of preoperative chem-
otherapy. Patients were randomly assigned to receive four
cycles of chemotherapy either before or after surgery. Chem-
otherapy consisted of four cycles of 5-fluorouracil 600 mg/m2,
epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2
(FEC) administered intravenously at 3-weekly intervals. In the
preoperative chemotherapy group, surgical therapy followed
within 4 weeks of the fourth course of chemotherapy. In the
postoperative chemotherapy group, the first cycle was given
within 36 hours after surgery. Patients not younger than 50
years received tamoxifen for 2 years. A total of 698 patients
were randomly assigned [8].
EORTC trial 22881 (1989 to 1996, median follow-up 5.1
years) was conducted to study the effect of an additional dose
of 16 Gy radiation to the tumor bed among early-stage breast
cancer patients who received 50 Gy radiotherapy after
lumpectomy. Patients with a microscopically incomplete
resection were assigned to receive boost doses of 10 or 26
Gy. Premenopausal patients with axillary lymph node involve-
ment received six cycles of adjuvant CMF, and all postmeno-
pausal patients received tamoxifen 20 mg per day during at
least 2 years. A total of 5,569 patients were enrolled [9].
In all trials, if adjuvant chemotherapy was indicated, patients
received either CMF or an anthracyclin-based regimen (FAC
or FEC). Adjuvant hormonal therapy for premenopausal hor-
mone receptor-positive patients was not yet recommended at
the time these trials were conducted. In the two oldest trials,
tamoxifen administration was not even recorded. This explains
the high number of patients for whom no information was
found on tamoxifen use. In the trials in which tamoxifen use
was recorded, less than 5% of patients 41 years old or
younger received tamoxifen. Therefore, we have to assume
that only a very small fraction of the patient population in this
study received tamoxifen.
Hormone receptor staining
Paraffin-embedded tumor material was collected from 480
patients 40 years old or younger. Tumors were histologically
graded using hematoxylin and eosin slides as described previ-
ously [10]. Immunohistochemical staining for ER and PgR sta-
tus was performed using a tissue microarray [11-14]. Three
core biopsies were taken from each tumor block and inserted
into a donor block. Immunohistochemical staining for ER was
performed using the monoclonal antibody DAKO-ER, 1D5
(DakoCytomation Denmark A/S, Glostrup, Denmark), for PgR
using the monoclonal antibody mPRI (TRANSBIO, Paris,
France). Immunohistochemical staining was scored using a
semiquantative system based on the percentage of positive
nuclei. After the percentage of positive nuclei in three core
biopsies was counted, the mean value was taken. For both ER
and PgR, tumors with greater than 10% of the tumor cells
showing nuclear staining were considered positive.
Statistical analysis
Analyses were performed for distant metastasis-free survival
(DMFS) and overall survival (OS). DMFS was defined as the
interval from time of randomization to time of distant metasta-
sis or death, whichever came first. OS was defined as timeAvailable online http://breast-cancer-research.com/content/9/5/R70
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from randomization to death from any cause. Survival curves
were estimated using the Kaplan-Meier method [15]. Differ-
ences in survival were analyzed using Cox proportional hazard
models [16]. The statistical analyses were performed using
SPSS software (SPSS Inc., Chicago, IL, USA). A direct com-
parison of patients who received chemotherapy versus those
who did not receive chemotherapy was not feasible. (This
would have introduced a selection bias in this retrospective
analysis as the vast majority of patients receiving chemother-
apy had positive axillary lymph nodes.) Therefore, conclusions
in this explorative analysis were based on indirect
comparisons.
Results
Participants
Paraffin-embedded tumor specimens were collected from 480
patients 40 years old or younger at the time of diagnosis
(Table 1). For 12 patients, ER status could not be scored, and
for 16 patients, PgR status could not be scored. Positive ER
status and positive PgR status were found in 288 and 223
patients, respectively. Two hundred patients received pro-
longed adjuvant systemic chemotherapy, whereas 279
patients did not receive adjuvant systemic chemotherapy. Of
the patients not receiving chemotherapy, 94% were node-
negative; 85% of patients who did receive chemotherapy were
node-positive. Characteristics related to adjuvant systemic
chemotherapy treatment are listed in Table 2. At the time of the
analysis, the median follow-up was 7.3 years, 106 (22%)
patients had died, and 155 (32%) patients developed a dis-
tant recurrence or died. The distribution of events stratified by
ER status is listed in Table 3.
Overall results
Estrogen receptor status
Overall, patients with ER-positive tumors had better OS rates
compared with ER-negative patients (hazard ratio [HR] 0.63,
95% confidence interval (CI) 0.43 to 0.93; P = 0.02) (Figure
1). Survival rates at 7 years were 82% for the ER-positive
group and 77% for the ER-negative group. DMFS rates were
70% for the ER-positive group and 66% for the ER-negative
group (HR 0.90, 95% CI 0.65 to 1.24; P = 0.51) (Figure 2).
Progesterone receptor status
PgR status yielded similar results: patients with progesterone-
positive tumors had better OS (HR 0.59, 95% CI 0.40 to 0.88;
P = 0.01). However, for DMFS this difference was not of sta-
tistical significance (HR 0.78, 95% CI 0.57 to 1.01; P = 0.14).
Patients who did not receive prolonged adjuvant 
chemotherapy
Estrogen receptor status
In patients who did not receive adjuvant systemic chemother-
apy, positive ER status was associated with better OS (HR
0.41, 95% CI 0.23 to 0.74; P < 0.01) (Figure 3). Survival rates
at 7 years were 90% for the ER-positive group and 77% for
the ER-negative group. Also, DMFS rates at 7 years were sig-
nificantly better for ER-positive patients: 80% versus 64% (HR
0.59, 95% CI 0.37 to 0.92; P = 0.02) (Figure 4).
Progesterone receptor status
In patients who did not receive adjuvant systemic chemother-
apy, positive PgR status was associated with better OS (HR
0.44, 95% CI 0.24 to 0.80; P < 0.01). Survival rates at 7 years
were 88% for the PgR-positive group and 75% for PgR-nega-
tive group. DMFS rates at 7 years were 79% for PgR-positive
patients and 67% for PgR-negative patients (HR 0.66, 95%
CI 0.42 to 1.04; P = 0.07).
Patients who received prolonged adjuvant systemic 
chemotherapy
Estrogen receptor status
In the group of 200 patients who did receive adjuvant systemic
chemotherapy, treatment outcome was not significantly
different between ER-positive and ER-negative breast cancer
patients. Survival rates at 7 years were 70% for the ER-posi-
tive group and 75% for the ER-negative group (HR 0.87, 95%
CI 0.50 to 1.52; P = 0.63) (Figure 5), and DMFS rates were
59% for the ER-positive group and 70% for the ER-negative
group (HR 1.36, 95% CI 0.82 to 2.26; P = 0.23) (Figure 6).
No further subgroup analyses specified by type of chemother-
apy were performed since these groups would have had insuf-
ficient numbers and events.
Progesterone receptor status
According to PgR status, no difference in treatment outcome
for patients who have received adjuvant systemic chemother-
apy was found. In both the PgR-positive and PgR-negative
patient groups, the survival rate at 7 years was 72% (HR 0.84,
95% CI 0.49 to 1.43; P = 0.51). Also, DMFS rates did not dif-
fer significantly between the PgR-positive group (59%) and
the PgR-negative group (64%) (HR 1.02, 95% CI 0.65 to
1.60; P = 0.93).
Multivariate analysis
Multivariate Cox regression OS analyses were performed sep-
arately for ER status and PgR status. Other covariates
included nodal status, tumor size, and the administration of
prolonged adjuvant chemotherapy. Both ER status (relative
risk [RR] 1.65) and PgR status (RR 1.56; data not shown)
remained independent prognostic factors with a significant
impact on OS (Table 4).
Discussion
This pooled analysis of patients 40 years old or younger dem-
onstrated that hormone receptor-positive patients experi-
enced no survival advantage of prolonged adjuvant CMF
chemotherapy compared with hormone receptor-negative
patients. However, in patients who did not receive adjuvant
chemotherapy, hormone receptor-positive status was associ-
ated with improved survival rates compared with hormoneBreast Cancer Research    Vol 9 No 5    van der Hage et al.
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receptor-negative status. In overall multivariate analyses, both
ER-positive status and PgR-positive status remained inde-
pendent prognostic factors of OS.
Our study has some limitations. First, the current analysis ret-
rospectively uses heterogeneous data from different rand-
omized trials. Second, adjuvant CMF chemotherapy to a large
extent has been replaced by anthracycline-containing
chemotherapeutic regimens because of higher treatment effi-
cacy in patients with breast cancer regardless of hormone
receptor or menopausal status [1]. Also, taxanes are increas-
ingly being used, showing additional survival benefits. There-
fore, different effects might have been demonstrated when
newer chemotherapy regimens were used throughout the
included studies. Third, the direct comparison between admin-
istration of chemotherapy versus no chemotherapy in hormone
receptor-positive and hormone receptor-negative patients
would have been very interesting. However, the confounding
effect of axillary lymph node status would have introduced a
significant selection bias because the majority of patients who
received chemotherapy had positive axillary lymph nodes. Nev-
ertheless, in multivariate analysis including axillary lymph node
Table 1
Characteristics of 480 breast cancer patients 40 years old or younger
Characteristic Number of patients (percentage) Total = 480
Clinical tumor size T1 185 (39)
T2/3 293 (61)
Missing data 2 (0)
Histological tumor size T1 292 (61)
T2/3 151 (31)
Missing data 37 (8)
Histological nodal status Negative 288 (60)
Positive 188 (39)
Missing data 4 (1)
Surgery Breast-conserving surgery 393 (82)
Mastectomy 86 (18)
Missing data 1 (0)
Adjuvant chemotherapy No 279 (58)
Yes 200 (42)
Missing data 1 (0)
Tamoxifena No 273 (57)
Yes 9 (2)b
Missing data 198 (41)
Histological grade I 70 (15)
II 145 (30)
III 255 (53)
Missing data 10 (2)
Estrogen receptor Positive 288 (60)
Negative 180 (38)
Missing data 12 (3)
Progesterone receptor Positive 223 (46)
Negative 241 (50)
Missing data 16 (3)
aDuring the period of time in which these trials were conducted, tamoxifen was not routinely given to premenopausal patients with estrogen 
receptor (ER)-positive tumors. bAll patients who received tamoxifen had ER-positive tumors. T, tumor size.Available online http://breast-cancer-research.com/content/9/5/R70
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status, tumor size, and the administration of prolonged adju-
vant chemotherapy, hormone receptor status remained an
independent prognostic factor for OS. Fourth, the survival
curves of the ER-positive and ER-negative group depicted in
Figure 5 (overall survival in patients receiving chemotherapy)
are crossing. This implies that that the proportional hazards
assumption is not justified. The rapid decrease in survival ben-
efit after a couple of years in the ER-positive group may well
be explained by the chemotherapy-induced amenorrhea and
the associated low estrogen levels. Unfortunately, no informa-
tion on the number of patients who have become amenor-
rheatic could be retrieved in order to test this hypothesis.
Despite these limitations, this pooled analysis of four rand-
omized controlled trials used individual patient data with
renewed pathological analysis of hormone receptor status.
Because less than 5% of the study population received
tamoxifen, the effect of chemotherapy alone in hormone recep-
tor-positive patients could be well studied. By analyzing hor-
mone receptor status centrally, we have provided
standardized measurements for all tumors in the study.
Table 2
Patient and tumor characteristics specified by adjuvant chemotherapya
Characteristic Number of patients (percentage)
No adjuvant chemotherapy Number = 279 Adjuvant chemotherapy Number = 200
ER-positive 161 (58) 126 (63)
Anthracycline-based 66
CMF 60
ER-negative 110 (39) 70 (35)
Anthracycline-based 48
CMF 22
PgR-positive 135 (48) 88 (44)
PgR-negative 135 (48) 105 (53)
T1 187 (67) 105 (53)
T2/T3 76 (27) 75 (38)
Node-negative 259 (93) 29 (15)
Node-positive 18 (6) 170 (85)
Breast-conserving surgery 247 (89) 146 (73)
Mastectomy 32 (11) 53 (27)
aMissing data not shown. CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; ER, estrogen receptor; PgR, progesterone receptor; T, tumor 
size.
Table 3
Distribution of events according to ER status and chemotherapya
Number of events (percentage)
No adjuvant chemotherapy Adjuvant chemotherapy
Deaths (number of events = 106)
ER-positive 19 (18) 35 (33)
ER-negative 29 (27) 19 (18)
Distant metastasis or death (number of events 
= 155)
ER-positive 37 (24) 54 (35)
ER-negative 38 (25) 21 (14)
aMissing data not shown. ER, estrogen receptor.Breast Cancer Research    Vol 9 No 5    van der Hage et al.
Page 6 of 9
(page number not for citation purposes)
Figure 1
Overall survival for all patients Overall survival for all patients. Estrogen receptor (ER)-positive patients 
have a better prognosis.
Figure 2
Distant metastasis-free survival for all patients Distant metastasis-free survival for all patients. There is no difference in 
prognosis according to estrogen receptor (ER) status.
Figure 3
Overall survival in patients who did not receive adjuvant chemotherapy Overall survival in patients who did not receive adjuvant chemotherapy. 
Estrogen receptor (ER)-positive patients have a better prognosis.
Figure 4
Distant metastasis-free survival in patients who did not receive adjuvant  chemotherapy Distant metastasis-free survival in patients who did not receive adjuvant 
chemotherapy. Estrogen receptor (ER)-positive patients have a better 
prognosis.Available online http://breast-cancer-research.com/content/9/5/R70
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Adjuvant systemic chemotherapy is a well-established treat-
ment modality in premenopausal breast cancer. In patients 35
years old or younger, administration of chemotherapy is advo-
cated regardless of nodal status, tumor size, or grade [3].
However, the efficacy of chemotherapy in premenopausal
patients with ER-positive breast cancer has been questioned
[5,17,18]. Our findings are in accordance with data from Aebi
and colleagues [5], who demonstrated that young premeno-
pausal patients with breast cancer treated with adjuvant CMF
chemotherapy had a higher risk of relapse and death than
older premenopausal patients, especially if their tumors were
ER-positive. In addition, several neoadjuvant chemotherapy
studies have demonstrated that patients with ER-negative
tumors are more likely to achieve a pathological complete
response than those with ER-positive tumors [19-21]. Moreo-
ver, these studies found that when patients with ER-negative
tumors achieved a pathological complete response their sur-
vival was comparable with that of ER-positive patients.
To optimize adjuvant systemic treatment in premenopausal
patients with breast cancer, several investigators have studied
the role of ovarian suppression by luteinizing hormone-releas-
ing hormone (LHRH) agonists. Recently, the Early Breast Can-
cer Overview group reported a meta-analysis of individual
patient data on the use of LHRH agonists [22]. When chemo-
therapy alone was compared with chemotherapy in combina-
tion with an LHRH agonist, a difference between younger and
older premenopausal women with hormone receptor-positive
disease was found. In patients 40 years old or younger, the
addition of an LHRH agonist significantly reduced the risk of
recurrence and death (HR 0.74; p = 0.01). This effect was
greatest in the group 35 years old or younger, whereas in the
group older than 40 years, the addition of an LHRH agonist
did not improve outcome. When chemotherapy alone was
compared with LHRH agonist with or without tamoxifen in
younger premenopausal patients with hormone receptor-pos-
itive tumors, the endocrine therapy improved outcome (mortal-
ity HR 0.82; P  = 0.15). Conversely, in hormone receptor-
negative patients, the same comparison significantly favored
treatment with chemotherapy (62.1% increased rate of recur-
rence or death; P = 0.003). To date, no trial has compared an
LHRH agonist against chemotherapy with tamoxifen in both
arms. This relevant and important issue needs to be resolved.
Although these results underline the fact that chemotherapy
may be equivalent to hormonal ovarian suppression in terms of
treatment outcome in hormone receptor-positive patients,
these results firmly demonstrate a beneficial effect of LHRH
agonists as additional therapy, especially in young patients
with breast cancer.
Three important ongoing trials are specifically investigating
ovarian function suppression (Suppression of Ovarian Func-
tion Trial, or SOFT), an aromatase inhibitor (Tamoxifen and
EXemestane Trial, or TEXT), and the need for chemotherapy
(Premenopausal Endocrine Responsive CHEmotherapy, or
Figure 5
Overall survival in patients who received adjuvant chemotherapy Overall survival in patients who received adjuvant chemotherapy. There 
is no long-term survival benefit for estrogen receptor (ER)-positive 
patients. The crossing lines could be explained by the initial beneficial 
effect of chemotherapy-induced amenorrhea.
Figure 6
Distant metastasis-free survival in patients who received adjuvant  chemotherapy Distant metastasis-free survival in patients who received adjuvant 
chemotherapy. There is no statistically significant difference in progno-
sis according to estrogen receptor (ER) status.Breast Cancer Research    Vol 9 No 5    van der Hage et al.
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PERCHE) in adjuvant treatment for young patients with hor-
mone receptor-positive breast cancer [23].
The 2005 St. Gallen Consensus Committee on adjuvant ther-
apy for early-stage breast cancer recommended that the first
consideration in treatment selection be endocrine responsive-
ness [24]. Three categories are identified: endocrine-respon-
sive, endocrine-nonresponsive, and tumors of uncertain
endocrine responsiveness. These categories refer to the
groups of tumors that are responsive to endocrine therapies
alone, chemotherapy alone, and chemotherapy and endocrine
therapy combinations, respectively. The 2005 Panel viewed
tamoxifen as a standard adjuvant treatment for premenopausal
endocrine-responsive patients. The combination of tamoxifen
with an LHRH agonist is recommended for very young
patients, especially in intermediate- and high-risk groups, and
for premenopausal patients of any age at high risk, especially
if chemotherapy did not induce amenorrhea. The use of aro-
matase inhibitors in premenopausal patients is not recom-
mended outside of clinical trials, except when tamoxifen is
contraindicated, especially in node-positive disease. Chemo-
therapy in addition to hormone therapy is advised for endo-
crine-responsive patients with node-positive disease.
Conclusion
In this retrospective pooled analysis of four studies using het-
erogeneous chemotherapy regimens, we have demonstrated
that treatment efficacy of adjuvant chemotherapy is less in
young patients with hormone receptor-positive tumors com-
pared with young patients with hormone receptor-negative
tumors. Therefore, we conclude that chemotherapy alone is
not a sufficient systemic treatment strategy in young patients
with hormone receptor-positive breast cancer. Hormone
responsiveness is the key for tailoring therapy for young
patients with breast cancer.
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